World's Best Scientists 2026 revealed!
Richard N. Fedorak

Richard N. Fedorak

D-Index & Metrics

Medicine

D-Index
99
Citations
46083
World Ranking
8464
National Ranking
328

Research.com Recognitions

  • 2011 - Fellow of the Royal Society of Canada Academy of Science

Overview

Richard N. Fedorak is affiliated with the University of Alberta in Canada. Their research primarily centers on the field of medicine, with notable contributions in several specialized subfields including epidemiology, genetics, health information management, surgery, and artificial intelligence.

The scientist's main topics of work span a range of areas related to gastrointestinal and healthcare technologies. These topics include:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Electronic Health Records Systems
  • Artificial Intelligence in Healthcare
  • Machine Learning in Healthcare
  • Biosimilars and Bioanalytical Methods

Frequent co-authors collaborating with Richard N. Fedorak comprise:

  • Reed T. Sutton
  • Karen I. Kroeker
  • Ellina Lytvyak
  • Levinus A. Dieleman
  • Farhad Peerani

Publication venues frequently featuring their work include:

  • Journal of the Canadian Association of Gastroenterology
  • npj Digital Medicine
  • Inflammatory Bowel Diseases
  • Digestive Diseases and Sciences
  • Crohn s & Colitis 360

Recent papers authored or co-authored by Richard N. Fedorak cover topics from clinical decision support systems to trends in surgical incidence and management of inflammatory bowel diseases. Notable recent publications include:

  • "An overview of clinical decision support systems: benefits, risks, and strategies for success" (2020), published in npj Digital Medicine
  • "Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis" (2020), published in Inflammatory Bowel Diseases
  • "Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease" (2020), published in Digestive Diseases and Sciences
  • "Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization" (2020), published in Crohn s & Colitis 360
  • "A162 OBESITY IS A RISK FACTOR FOR THE DEVELOPMENT OF THE EXTRAINTESTINAL MANIFESTATIONS IN ULCERATIVE COLITIS, BUT NOT IN CROHN'S DISEASE" (2021), published in Journal of the Canadian Association of Gastroenterology

Richard N. Fedorak was awarded the designation of Fellow of the Royal Society of Canada in 2011 within the Academy of Science.

Best Publications

  • Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

    Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey

  • Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

  • An overview of clinical decision support systems: benefits, risks, and strategies for success.

    Reed T. Sutton;David Pincock;Daniel C. Baumgart;Daniel C. Sadowski

  • Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

    William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

  • Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

    Brian G Feagan;Gordon R Greenberg;Gary Wild;Richard N Fedorak

  • Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

    Karen L. Madsen;Jason S. Doyle;Laurence D. Jewell;Michele M. Tavernini

  • Methotrexate for the Treatment of Crohn's Disease

    B G Feagan;J Rochon;R N Fedorak;E J Irvine

  • VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

    Rodrigo Bibiloni;Richard N Fedorak;Gerald W Tannock;Karen L Madsen

  • A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

    B G Feagan;R N Fedorak;E J Irvine;G Wild

  • The epidemiology of inflammatory bowel disease in Canada: a population-based study.

    Charles N Bernstein;Andre Wajda;Lawrence W Svenson;Adrian MacKenzie

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

    Stefan Schreiber;Paul Rutgeerts;Richard N. Fedorak;Munaa Khaliq–Kareemi

  • Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    Stephan R. Targan;Brian G. Feagan;Richard N. Fedorak;Bret A. Lashner

  • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

    William J. Sandborn;Brian G. Feagan;Richard N. Fedorak;Ellen Scherl

  • Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

    Richard N. Fedorak;Alfred Gangl;Charles O. Elson;Paul Rutgeerts

  • Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

    E. J. Irvine;B. Feagan;J. Rochon;A. Archambault

  • Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.

    S.J.H. van Deventer;C.O. Elson;R.N. Fedorak

  • The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting.

    Alan Barkun;Sandrine Sabbah;Robert Enns;David Armstrong

  • World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011.

    Francisco Guarner;Aamir G. Khan;James Garisch;Rami Eliakim

Frequent Co-Authors

Brian G. Feagan
Brian G. Feagan University of Western Ontario
Remo Panaccione
Remo Panaccione University of Calgary
William J. Sandborn
William J. Sandborn University of California, San Diego
Stefan Schreiber
Stefan Schreiber Kiel University
Gilaad G. Kaplan
Gilaad G. Kaplan University of Calgary
Subrata Ghosh
Subrata Ghosh University College Cork
Stephen B. Hanauer
Stephen B. Hanauer Northwestern University
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the US doesn’t always follow a single path. For those seeking different entry points or advancement opportunities in healthcare, there are several flexible online degree options tailored to various needs.

Registered Nurses can take advantage of online rn to bsn programs without clinical requirements. These programs allow working professionals to further their education on their own schedule and without the need for in-person practice hours.

Aspiring leaders and practitioners interested in a Doctor of Nursing Practice (DNP) can consider dnp online programs for a flexible format. Additionally, students looking to accelerate their study can choose from the dnp program without clinical hours—ideal for those wanting a streamlined approach to advanced roles.

Entry-level positions are also accessible, thanks to options like the lpn program. Fast-track online LPN programs make it possible to start your career in patient care quickly and affordably.

Best Scientists Citing Richard N. Fedorak

Trending Scientists